Animal Health
Intellectual Property
Management Skills
Medical Devices
Support Staff

Sponsoring & Exhibiting

For sponsorship and exhibition opportunities at Management Forum events click here

Event Management

To find out about event management click here

Speaking Opportunities

Speaking opportunities are available on selected Management Forum events, please contact us for further information

Management Forum Brochure

Download our catalogue here

Pharmaceutical Medical Devices

Injectable Drug Delivery

21-22 Mar 2017

Standard 1399 1959 2182
Early 1199 1679 1870
Excluding VAT @ 20.00%

Book by 6 Feb to get the early booking price shown above.

Venue: Le Meridien Piccadilly Hotel, London

Enrol now

Select currency when checking out

Bespoke training

We can customise this course to meet the requirements of your organisation.

Learn more

Course Overview

Advances in Technology for pens, auto-injectors, needle-free, pre-filled syringes and other parenteral methods, plus a regulatory update

The pharmaceutical industry continues to face huge change with the world’s largest selling drugs having switched from oral small molecules (tablets), taken by millions of patients costing about £1 per day to biologics, taken by fewer people but costing many times as much. Four of the world’s five top selling drugs are now delivered by injection or infusion and the remaining member of the top 5 list is inhaled. Thus the world’s 5 top selling drugs all require a device to effect delivery.

Since injections have never been particularly popular with patients, the emphasis is increasingly on making patients take their drugs by applying ergonomic factors and compliance monitoring to drug delivery. This conference will discuss the state-of-the-art technology being applied in the parenteral field and will look at advances in compliance monitoring.

Also of interest

We are running the sister event to this meeting Pre-Filled Syringes this March and if you require more information on this or any other meeting please call Customer Services on +44 (0)20 7749 4730 or e-mail

Why you should attend

  • Hear the latest technology in the injectable drug delivery arena
  • Establish where this fast moving market is going and the innovations being applied for patient compliance
  • Network with your peers and increase your business partnership potential

Who should attend

This conference will be of particular interest to:
Scientists and management in medical devices, pharmaceutical and biotechnology companies working in parenteral delivery. Personnel responsible for device programmes, product development, regulatory affairs and product lifecycle management will find this event beneficial. Previous delegates include: Directors, Senior Executives in R&D, Head of Device Departments, Combination Products Specialists, Drug Delivery Managers, Business Development Executives, Product Development Managers and those in Project Co-ordination and Marketing roles.

Programme Day One

Please note, this is the 2016 programme and the 2017 programme will be available shortly

09.00 Registration and coffee

09.30 Chairman’s Welcome and Introduction
Dr Gregory Berman, Head of Medical, Kinneir Dufort, UK

09.40 Speeding up Time to Market with Platform Products and Customer-Specific Customization of Pens and Auto-injectors

  • New pharma demands for complex injection devices
  • Usability and design considerations for pen and autoinjector devices
  • Advantages of large scale automated manufacture of pen injector and autoinjector subassemblies

Ian Thompson, Vice President Business Development, Ypsomed, UK

10.20 Lifecycle Management: the Bydureon Pen

  • Challenges and opportunities

Josie Wright, Principal Scientist (Device Development), AstraZeneca, UK

11.00 Discussion

11.10 Refreshments

11.30 Novel Aseptic Foil Sealing Development for a New Auto-Injector

  • Challenges and demands expected for aseptic manufacturing of this device
  • The technology and how we developed the solution

Simon Strothers, Director, 3PInnovation, UK and Matthew Young, Chief Technology Officer, Oval Medical Technologies, UK

12.10 Trends Towards Large Volume Pumps

Tony Bedford, Head of Medical Business Development, Kinneir Dufort, UK

12.50 Discussion

13.00 Lunch

14.10 Transforming the Patient Experience with a Computer-Controlled Needle-Free Device

  • Delivering high viscosity, high concentration biologics is a challenge for the biopharma industry. Injections are slow and painful, and patients don’t like needles. Drug adherence is a problem and safety concerns are real
  • The Portal device offers a transformed patient experience. The injection is needle-free, fast, imperceptible and the device is easy to use. It is also agnostic to the drug’s viscosity and concentration via computer control
  • We will present our pre-clinical data and early results from our patient tolerability study

Patrick Anquetil, CEO & Co-Founder, Portal Instruments, USA

15.00 Injected Drug Delivery: The Challenge and Opportunity Offered by Connectivity

  • Brief introduction to Connected Health
  • Patient Support Programmes enabled by Connectivity
  • Perspectives of stakeholders: Patients, Clinicians, HCPs, Pharma, Payers Incentives and Barriers
  • Device Connectivity models and architectures.

Diarmuid Quinn, Director of Sales and Business Development, Connected Health Solution Design, S3 Group, Ireland

15.30 Discussion

15.40 Refreshments

16.00 SteadyMed’s Patchpump TM Technology

  • A wearable, discreet, water-resistant and disposable drug administration technology
  • Design & manufacturing status of Trevyent for Pulmonary Arterial Hypertension
  • Next generation PatchPump concepts

Assaf Shaked, Senior Manager, Device Development, SteadyMed Therapeutics, USA

16.40 The Requirements and Unique Challenges in the Testing of On-Body Delivery Systems

  • Summary of Draft ISO 11608-6 Standard on On-Body Delivery Systems
    • Device and Pharmaceutical Requirements
  • Regulatory approval paths – USA/EU
  • Pump vs. Injector
  • Unique Challenges
    • Sterilization/Sterility
    • Product Contact – Reservoir, fluid path
    • Adhesives – retention, removal and skin reactions
    • Filling
    • Usability

Lee Leichter, President P/L Medical, USA

17.20 Discussion

17.30 End of Day One

19.30 Drinks reception followed by dinner for delegates and speakers at Le Meridien Hotel, London

Programme Day Two

Please note, this is the 2016 programme and the 2017 programme will be available shortly

09.00 Review of Day One

Dr Gregory Berman, Head of Medical, Kinneir Dufort, UK

09.10 What do Pharma Companies Want from Device Manufacturers?
Speaker (invited)

09.50 Get Out There and Listen

  • Why medical devices have to be desirable, as well as safe and effective, to compete in their competitive set
  • Should human factors include emotional factors?
  • Does your medical device have a competitive advantage?
  • Should medical devices be thought of as brands?
  • How successful devices from other industries are the ones that bond emotionally (as well as deliver functionally)
  • Good and bad examples from other industries

Craig Scott, Director, Greensand and Martin Schlaeppi, Director, Greensand, UK

10.30 Discussion

10.40 Refreshments

11.10 Improving Adherence for Injectable Drugs

  • Importance of adherence, outcomes and connected health
  • Economic and health impact of non-adherence in the market today
  • Historic approaches to improving adherence
  • Case studies of Connected Health approaches to adherence
  • Strategies for implementing solutions for injection devices

Zach Marks, Director, Delivery Systems Marketing, West Pharmaceutical Services, USA

11.50 Leveraging a Device Platform – Some of the Considerations

  • What is a ‘platform’ ?
  • Client vs. Provider responsibilities
  • Documentation and structure
  • Risks
  • Change management
  • A Case Study

Mark Chipperfield, Company Director and Principal Consultant, Corvus Device, UK

12.30 Discussion

12.45 Lunch

14.00 High Viscosity, High Volume (HVHV)

  • Current challenges to delivery
  • Overview of existing solutions
  • Modelling HVHV delivery in patient
  • Outlook to 2nd generation solutions

Uri Baruch, Head of Drug Delivery, Cambridge Design Partnership, UK

14.40 User Interface (UI) Design Considerations for Electronic Drug Delivery Devices

  • UI design considerations for electronic auto injectors.
  • Opportunities and challenges with injectable drug delivery devices
  • New horizons for healthcare products

Tsachi Shaked, Senior Director of Marketing and Business Development Injectable Drug Delivery Devices Elcam Medical, Israel

15.20 SAN-DVs, Safe Auto-Needles for Use with Drugs in Vials – Combining the SAN-L for Self-Administration or the SAN-Light for Administration by Health Care Professionals

  • Case study showing the products evolution and lessons learnt from human factors studies with patients and Health Care Professionals (HCPs)

David Daily, CEO and Co-Founder and Hagay Drori, Product Manager, DALI Medical Devices, Israel

16.00 Discussion and Chairman’s Closing Remarks

16.15 End of Conference and Tea


Gregory Berman

Gregory Berman is Head of the Medical Group at Kinneir Dufort, an award-winning research, innovation, design and product development company, with over 30 years’ experience helping companies discover, create, develop and realise tangible new products, brands and experiences.
He helps clients in the life-science, medical and healthcare sectors to develop products in complex situations, optimise life-science R&D and exploit technology strategically. For example he:
Led the design and development of SmartJect™; an autoinjector which automatically retracts the needle and was launched by J&J in 2010 with an important next-generation drug.
Worked with Chrono Therapeutics, helping to develop their SmartStop™ based device, the world’s first programmable, wearable transdermal smoking cessation therapy.
Participated in a detailed design review of an autoinjector being developed by a leading pharmaceutical company for a new drug.
Undertook the Voice of Customer study for a leading biopharmaceutical company, as the starting point for developing high volume parenteral delivery devices for lifesaving immunotherapies.
Undertook a technology survey for a company interested in needle-free, transdermal, micro-needle, electroporation and iontophoresis drug delivery devices.
Developed the business plan and identified partners for a quoted UK drug delivery company to develop a new drug formulation technology they had in-licensed
Has worked extensively with start-up drug delivery companies to help commercialise the technology.
He has also conducted a number of due diligence and technology assessments e.g.:
On behalf of Trinity Biotech Plc. (listed on NASDAQ) undertook the due diligence on Fiomi Diagnostics. Subsequently Trinity acquired Fiomi for $13.1m, strengthening its position in the growing $900m point-of-care cardiac biomarker diagnostics market.
For a UK plc evaluated a company developing a needless injector.

For a multinational assessed a small company developing an autoinjector

For a UK drug delivery plc evaluated a privately held US formulations group

An experts report for the offering memorandum for a French company producing therapeutic proteins.

Nic Bowman

Nic Bowman is the head of the Devices Centre of Excellence (DCoE) at Pfizer Ltd, based in Cambridge in the UK. He has a BSc in Mechanical Engineering from Bath University, England (1984).

Nic worked initially in the energy sector, firstly engineering in coal mining, and then in oil exploration, reaching the role of Chief Mechanical Engineer for Sperry Sun in 1993.

Between 1993 and 2006 he worked for The Technology Partnership, Cambridge, UK, specialising in drug delivery devices. During this period Nic worked with a number of pharma and device companies, developing a range of breath actuated Metered Dose Inhalers (MDIs), MDI counters and Dry Powder Inhalers.

Between 2006 and 2008 Nic worked as Head of Medical Product Development for Sagentia, Cambridge, UK. He built up Sagentia’s pharma experience and portfolio.

Nic moved to Pfizer in 2008 and as Director of Device Design and Development with responsibility for the design and development of novel drug delivery devices for Pfizer. He was promoted to Senior Director in 2010, and to Head of DCoE in 2011.

Nic is a Fellow of the Institution of Mechanical Engineers. He is a regular conference speaker, and is named in more than 20 patents.

Ian Thompson

Ian Thompson, Vice President Business Development, Delivery Systems, has been with Ypsomed AG since 1995 in a number of roles in key account management and business development working with pharma companies to develop and bring to market innovative self-injection systems.
He studied biochemistry and biotechnology in the UK from 1979-1983 and has worked in medical device companies since moving to Switzerland in 1990.
Following the successful development and launch of a range of new pen and autoinjector custom products, Ypsomed Delivery Systems’ continues to focus on the development of next generation pen, autoinjector and bolus injector technologies.

Patrick Anquetil

Dr. Patrick Anquetil is Portal Instrument’s Chief Executive Officer. He brings more than 18 years of experience in nanotechnology, including extensive knowledge in the areas of cleantech, material science, and instrumentation.
From 2009 to 2012, he was co-founder and director of strategic and process planning for SynapDx Corporation, where he had responsibility for development of the company’s business and operational plans as well as securing $9 million in Series A funding. He began his career as a science and nanotechnology equity research analyst at Susquehanna International Group, authoring and marketing nanotechnology industry and equity research reports to hedge funds and portfolio managers. He holds a doctorate in bio-instrumentation from MIT, an MBA from Harvard University, and a master’s degree from the ETH in Zurich and the University of Tokyo. His work has appeared in numerous peer-reviewed publications as well as mainstream media, including MIT Technology Review, Wired Magazine, PBS, and CNBC among others.

Uri Baruch

Uri Baruch is Head of Drug Delivery, Cambridge Design Partnership

Philippe Lauwers

Philippe Lauwers is Business Unit Director Pre-Filled Syringes at Nipro PharmaPackaging (NPP); a division of Nipro Corporation.

NPP is a global, vertically integrated primary packaging manufacturer with a broad product portfolio and knowledge, giving unparalleled industry know-how and expertise.

Mr. Lauwers graduated in Biotechnology from the University in Ghent, Belgium and worked as a scientific researcher at the Catholic University of Leuven.

Upon obtaining an additional degree in Biomedical Engineering at the Catholic University of Leuven he moved from an academic to an industrial environment.

He has been active in the Medical and Pharma packaging sector for the last 10 years in various roles.

He joined Nipro PharmaPackaging in January 2016 and is involved in technical and scientific discussions with customers, as well as in scientific marketing and business development activities.

You may also be interested in...

Pre-Filled Syringes

Previous customers include...

  • Actavis
  • Actavis Biologics Ltd
  • Advanex Europe Ltd
  • ALK Abello
  • ALK-Abello A/S
  • American Medical Systems
  • Antares Pharma Inc
  • Battelle
  • Consort Medical plc
  • Dainippon Sumitomo Pharma Co Ltd
  • Eveon SA
  • German Malaysian Medical Industries
  • Halozyme Therapeutics Inc
  • Haselmeier GmbH
  • Ian Smith
  • Komax Systems LCF SA
  • Mikron SA Boudry
  • Nelipak bv
  • PDD GROUP Limited
  • Pfizer
  • Salvus Technology Limited
  • Sensile Medical AG
  • SHL Group AB
  • Takeda Pharma A/S
  • Teamtechnik Maschinen und Anlagen GmbH
  • Limited
  • Veterinary Medicines Directorate
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • West Pharmaceutical Services Cornwall Ltd
  • Xellia Pharmaceuticals